Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Adverse Effect of Polatuzumab Vedotin in Patients With Diffuse Large B Cell Lymphoma: an Observation Study

NCT05006534 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05006534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05006534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Adverse Effect of Polatuzumab Vedotin in Patients With Diffuse Large B Cell Lymphoma: an Observation Study
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Completed
Start date
June 1, 2020
Completion date
June 29, 2021
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory lymphoma, relapsed non hodgkin lymphoma